Reoviruses, short for Respiratory Enteric Orphan viruses, are a family of double-stranded RNA viruses with potential applications in oncolytic virotherapy. One member of the Reoviridae family, the mammalian orthoreovirus type 3 (Reovirus serotype 3, Dearing strain), has shown promise in selectively targeting and destroying cancer cells. Research into oncolytic reoviruses involves exploiting their ability to replicate preferentially in cells with activated Ras signaling pathways commonly found in cancer cells. Preclinical and clinical studies have demonstrated the safety and efficacy of oncolytic reoviruses against a variety of cancers, including gliomas, breast cancer, and ovarian cancer. The virus induces cancer cell death while sparing normal cells, making it a potential therapeutic option. The mechanism of action involves both direct viral oncolysis and the stimulation of antitumor immune responses. Ongoing research aims to optimize the use of oncolytic reoviruses, exploring combination therapies with other cancer treatments and addressing challenges such as the development of neutralizing antibodies. The field of oncolytic virotherapy continues to evolve, and reoviruses hold promise as a novel and innovative approach to cancer treatment.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain